September 2022 - 4D Lifetec one of the winners of the 2022 Healthcare & Pharmaceutical Awards



As a company located in Switzerland, 4D Lifetec AG has developed over the past 7 years a reliable and standardized high throughput liquid biopsy technology for the detection of cancer already at very early stages of lung- colon-, breast- and prostate cancer. Our 4D Lifetest™ assay, based on a proprietary unique transformational biomarker and backed by clinical data and several IVD-CE marks, has the potential to detect the most relevant types of cancer from a blood sample with high sensitivity and remarkably earlier than genomic assays. Arne Faisst, CEO of 4D Lifetec said about the award: "It's great to be recognized in this way by GHP, especially since we’ve been able to develop this technology in Switzerland. It has the potential to become the first assay on the market to fulfil a central promise of liquid biopsy. It therefore is also important for me to link this success with a big thank you to all our supporters such as clinics, investors or partners and especially to the entire team of 4D Lifetec".


GHP Magazine have been running the Healthcare & Pharmaceutical Awards awards now for eight years, with the goal of recognizing different companies from across the healthcare and pharmaceutical industries. Regardless of their size and reach, nominees within the Healthcare & Pharmaceutical Awards will be assessed and independently judged purely on merit and excellence based on a variety of publicly accessible sources which are assessed alongside any material supplied by a nominating party or the nominee themselves. Final judgement is cast based on various criteria, including business performance, longevity, business growth, significant innovations and client feedback.


For more information visit:

The original press release you will find here: